An emerging strategy for targeted therapy of pulmonary arterial hypertension: Vasodilation plus vascular remodeling inhibition

Simonneau, 2019, Haemodynamic definitions and updated clinical classification of pulmonary hypertension, Eur Respir J., 53, 1801913, 10.1183/13993003.01913-2018 Benza, 2012, An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry, Chest., 142, 448, 10.1378/chest.11-1460 Farber, 2015, Five-year outcomes of patients enrolled in the REVEAL Registry, Chest., 148, 1043, 10.1378/chest.15-0300 Duffels, 2007, Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry, Int J Cardiol., 120, 198, 10.1016/j.ijcard.2006.09.017 Humbert, 2019, Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives, Eur Respir J, 53, 1801887, 10.1183/13993003.01887-2018 Spiekerkoetter, 2019, New and emerging therapies for pulmonary arterial hypertension, Annu Rev Med, 70, 45, 10.1146/annurev-med-041717-085955 Schermuly, 2011, Mechanisms of disease: pulmonary arterial hypertension, Nat Rev Cardiol, 8, 443, 10.1038/nrcardio.2011.87 Lajoie, 2016, Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis, The Lancet Respiratory Medicine, 4, 291, 10.1016/S2213-2600(16)00027-8 Burks, 2018, Pulmonary arterial hypertension: combination therapy in practice, Am J Cardiovasc Drugs, 18, 249, 10.1007/s40256-018-0272-5 Hu, 2020, Discovery of novel pyrazolo[3,4-b] pyridine derivatives with dual activities of vascular remodeling inhibition and vasodilation for the treatment of pulmonary arterial hypertension, J Med Chem, 63, 11215, 10.1021/acs.jmedchem.0c01132 EM Lau, Y Tamura, MD McGoon, O Sitbon, The 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress. Eur Respir J 46: (2015) 879–882. Sommer, 2021, Current and future treatments of pulmonary arterial hypertension, Br J Pharmacol, 178, 6, 10.1111/bph.15016 Grunig, 2018, General measures and supportive therapy for pulmonary arterial hypertension: updated recommendations from the Cologne Consensus Conference 2018, Int J Cardiol, 272S, 30, 10.1016/j.ijcard.2018.08.085 O’Callaghan, 2011, Treatment of pulmonary arterial hypertension with targeted therapies, Nat Rev Cardiol, 8, 526, 10.1038/nrcardio.2011.104 Thenappan, 2018, Pulmonary arterial hypertension: pathogenesis and clinical management, BMJ, 360 Barnes, 2019, Phosphodiesterase 5 inhibitors for pulmonary hypertension, Cochrane Database Syst Rev 1, CD012621 Huang, 2019, Validation of Phosphodiesterase-10 as a novel target for pulmonary arterial hypertension via highly selective and subnanomolar inhibitors, J Med Chem, 62, 3707, 10.1021/acs.jmedchem.9b00224 Yang, 2020, Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension, Acta Pharm Sin B, 10, 2339, 10.1016/j.apsb.2020.04.003 Mayeux, 2021, Management of pulmonary arterial hypertension, Curr Cardiovasc Risk Rep, 15, 2, 10.1007/s12170-020-00663-3 Guignabert, 2013, Pathogenesis of pulmonary arterial hypertension: lessons from cancer, Eur Respir Rev, 22, 543, 10.1183/09059180.00007513 Sutendra, 2014, The metabolic basis of pulmonary arterial hypertension, Cell Metab, 19, 558, 10.1016/j.cmet.2014.01.004 Sun, 2013, An AMPK paradox in pulmonary arterial hypertension, Journal of Biomedical Science and Engineering, 06, 1085, 10.4236/jbise.2013.611136 Boucherat, 2018, Mitochondrial Hsp90 accumulation promotes vascular remodeling in pulmonary arterial hypertension, Am J Respir Crit Care Med, 198, 90, 10.1164/rccm.201708-1751OC Tielemans, 2019, TGF-beta and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension, Drug Discov Today, 24, 703, 10.1016/j.drudis.2018.12.001 Yung, 2016, A selective transforming growth factor-β ligand trap attenuates pulmonary hypertension, Am J Respir Crit Care Med, 194, 1140, 10.1164/rccm.201510-1955OC Van der Feen, 2019, Multicenter preclinical validation of BET inhibition for the treatment of pulmonary arterial hypertension, Am J Respir Crit Care Med, 200, 910, 10.1164/rccm.201812-2275OC Meloche, 2014, Role for DNA damage signaling in pulmonary arterial hypertension, Circulation, 129, 786, 10.1161/CIRCULATIONAHA.113.006167 Grinnan, 2019, Drug repositioning in pulmonary arterial hypertension: challenges and opportunities, Pulm Circ, 9, 10.1177/2045894019832226 Negi, 2021, Computational repurposing of therapeutic small molecules from cancer to pulmonary hypertension, Sci Adv, 7, eabh3794, 10.1126/sciadv.abh3794 Grobs, 2021, Preclinical investigation of trifluoperazine as a novel therapeutic agent for the treatment of pulmonary arterial hypertension, Int J Mol Sci, 22, 2919, 10.3390/ijms22062919 Rastogi, 2016, Traditional herbs: a remedy for cardiovascular disorders, Phytomedicine, 23, 1082, 10.1016/j.phymed.2015.10.012 Ma, 2021, Plant natural products: promising resources for cancer chemoprevention, Molecules, 26, 933, 10.3390/molecules26040933 Lee, 2021, Traditional Chinese herbal medicine at the forefront battle against COVID-19: clinical experience and scientific basis, Phytomedicine, 80, 10.1016/j.phymed.2020.153337 Xiang, 2018, Natural plant products in treatment of pulmonary arterial hypertension, Pulm Circ, 8, 10.1177/2045894018784033 Zhao, 2016, Mechanisms and clinical application of tetramethylpyrazine (an interesting natural compound isolated from Ligusticum wallichii): current status and perspective, Oxid Med Cell Longev, 2016, 2124638, 10.1155/2016/2124638 Cai, 2014, Inhibition of angiogenesis, fibrosis and thrombosis by tetramethylpyrazine: mechanisms contributing to the SDF–1/CXCR4 axis, PLoS ONE, 9 Guo, 2016, Cardiovascular actions and therapeutic potential of tetramethylpyrazine (active component isolated from rhizoma chuanxiong): roles and mechanisms, Biomed Res Int, 2016, 2430329, 10.1155/2016/2430329 Courboulin, 2012, Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH, Eur Respir J, 40, 618, 10.1183/09031936.00084211 Dumas, 2010, Dehydroepiandrosterone: a new treatment for vascular remodeling diseases including pulmonary arterial hypertension, Pharmacol Ther, 126, 186, 10.1016/j.pharmthera.2010.02.003 Nan, 2018, Bioactive fraction of Rhodiola algida against chronic hypoxia-induced pulmonary arterial hypertension and its anti-proliferation mechanism in rats, J Ethnopharmacol, 216, 175, 10.1016/j.jep.2018.01.010 Kosanovic, 2013, Rhodiola: an ordinary plant or a promising future therapy for pulmonary hypertension?, A brief review. Pulm Circ, 3, 499, 10.1086/674303 Huang, 2015, Salidroside attenuates chronic hypoxia-induced pulmonary hypertension via adenosine A2a receptor related mitochondria-dependent apoptosis pathway, J Mol Cell Cardiol, 82, 153, 10.1016/j.yjmcc.2015.03.005 Chen, 2016, S Salidroside exerts protective effects against chronic hypoxia-induced pulmonary arterial hypertension via AMPKα1-dependent pathways, Am J Transl Res, 8, 12 Mirhadi, 2021, Resveratrol: mechanistic and therapeutic perspectives in pulmonary arterial hypertension, Pharmacol Res, 163, 10.1016/j.phrs.2020.105287 Wang, 2016, Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1, J Vasc Surg, 64, 1468, 10.1016/j.jvs.2015.09.016 Galie, 2015, Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension, N Engl J Med, 373, 834, 10.1056/NEJMoa1413687 Pulido, 2013, Macitentan and morbidity and mortality in pulmonary arterial hypertension, N Engl J Med, 369, 809, 10.1056/NEJMoa1213917 Ghofrani, 2013, Riociguat for the treatment of pulmonary arterial hypertension, N Engl J Med, 369, 330, 10.1056/NEJMoa1209655 Sitbon, 2015, Selexipag for the treatment of pulmonary arterial hypertension, N Engl J Med, 373, 2522, 10.1056/NEJMoa1503184 Sitbon, 2016, Beyond a single pathway: combination therapy in pulmonary arterial hypertension, Eur Respir Rev, 25, 408, 10.1183/16000617.0085-2016 Mandras, 2021, Combination therapy in pulmonary arterial hypertension-targeting the nitric oxide and prostacyclin pathways, J Cardiovasc Pharmacol Ther, 26, 453, 10.1177/10742484211006531 Haarman, 2021, Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension, Eur Respir J, 57, 2001120, 10.1183/13993003.01120-2020 Momoi, 2021, Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension, Ther Adv Respir Dis, 15, 10.1177/1753466621995048 Chin, 2021, Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension, J Am Coll Cardiol, 78, 1393, 10.1016/j.jacc.2021.07.057 Dumas, 2018, NMDA-type glutamate receptor activation promotes vascular remodeling and pulmonary arterial hypertension, Circulation, 137, 2371, 10.1161/CIRCULATIONAHA.117.029930 Luo, 2021, Dual-functional MN-08 attenuated pulmonary arterial hypertension through vasodilation and inhibition of pulmonary arterial remodeling, Hypertension, 77, 1787, 10.1161/HYPERTENSIONAHA.120.15994 Cheng, 2018, Identification of a novel hybridization from isosorbide 5-mononitrate and bardoxolone methyl with dual activities of pulmonary vasodilation and vascular remodeling inhibition on pulmonary arterial hypertension rats, J Med Chem, 61, 1474, 10.1021/acs.jmedchem.7b01153